CB-5083

Inhibitor of VCP

Structure

Information

Protein target names: VCP

Mechanism of action: Inhibitor

Recommended in-cell concentration:
up to 1 uM

In Vitro Validations

Uniprot ID: P55072
Target Class: ATPase
Target SubClass: AAA+
Potency: IC50
Potency Value: 11 nM
Potency Assay: ATPase assay
PDB ID for probe-target interaction (3D structure): 6MCK
Structure-activity relationship: yes
Target aliases:
Transitional endoplasmic reticulum ATPase, TERA_HU ...

DOI Reference: 10.1016/j.ccell.2015.10.002

In Cell Validations

In Vivo Data

I have extra information to add

SERP ratings and comments


SERP Ratings

In Cell Rating
In Model Organisms

SERP Comments:

CB-5083 has been well characterized in terms of its PK profile and cellular activity. In terms of selectivity, it appears to have only been counter-screened in ATPase and kinase panels. The subsequent report by others that it inhibits PDE6, and is indeed only 8-fold selective over PDE6, serves to provide a reminder that any results obtained with CB-5083 should be interpreted with caution as other pharmacology may be at play.

(last updated: 13 Sept 2021 )

SERP Ratings

In Cell Rating
In Model Organisms

SERP Comments:

Choice of concentration is cell-line dependent and is also indication-dependent, most likely. If cytotoxicity is not a desired pharmacological response, using submicromolar concentration may be preferred. Testing at 2 or 3 concentrations would be the most informative approach in such a case. While the listed dose may be suitable, a higher dose - 75 mg/kg QD in mice - is also tolerated and may thus be explored, depending on the indication.

(last updated: 23 Sept 2021 )

SERP Ratings

In Cell Rating
In Model Organisms

SERP Comments:

This is a well-characterized probe recommended for use in cells and in mice. A wide range of biochemical and cellular measurements support a direct effect on VCP/p97. Notably, resistant alleles have been identified by selection from HCT116 cells. Mouse PK (IV and PO) is available, and numerous studies measuring VCP modulation and downstream cancer phenotypes have been reported using oral administration of 100 mpk CB-5083.

(last updated: 11 Oct 2021 )